Anthropic’s revenue reaches $16.3 billion in the first half as it is said to seek a $2 trillion IPO valuation

Anthropic’s revenue surged to $16.3 billion in the first half of 2026, up from $1.1 billion in an earlier period, according to reported figures^3,4. The company is reportedly targeting a $2 trillion valuation for its anticipated initial public offering¹.

Anthropic’s latest private valuation has reached roughly $965 billion, with a potential public listing this year at a valuation of as much as $2 trillion⁵. The company could list as early as mid-November^3,6.

Anthropic reportedly filed a draft S-1 registration statement, and a public S-1 is expected as soon as 26 October^7,8. Prospective investors have been waiting for that document, which has not yet been made public³.

Why it matters to investors

The listing is holding up the wider new-issue market. The IPO market has been in a lull as investors wait for Anthropic to file its S-1, while biotech companies have quietly dominated the listings that have gone ahead².

A $2 trillion target would be roughly double the $965 billion private valuation, and the S-1 would give public investors their first detailed look at the business behind those figures^5,7. Analysts writing about the revenue numbers argue that the growth could support a higher expected IPO valuation⁴.

Valuation expert Aswath Damodaran has warned that the metrics IPO investors rely on can be erratic and heavily influenced by market sentiment⁹. Costs are also large: commentary on the company has put its compute bill at $750B¹⁰. The company itself warns that AI could cause mass unemployment, even as it seeks a $2 trillion valuation¹.

The listing would also set a reference point for rivals. OpenAI is seeking a $30 billion round at a $1.25T-$1.4T valuation⁶, and Nvidia has a $170 billion backstop for neocloud companies¹⁰.

What to watch

The public S-1 is the key document: it would confirm or revise the reported revenue, costs and valuation, and set the timetable for a listing as early as mid-November^3,8.

Prediction-market traders are already betting on whether Anthropic will trade under the $ANT ticker⁷.

A successful listing could reopen the IPO pipeline beyond biotech, while a delayed or weaker one would extend the lull that has kept other issuers waiting².